Country: European Union
Language: English
Source: EMA (European Medicines Agency)
adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)
Janssen-Cilag International NV
J07BN02
COVID-19 vaccine (Ad26.COV2-S [recombinant])
Vaccines
COVID-19 virus infection
Jcovden is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.The use of this vaccine should be in accordance with official recommendations.
Revision: 30
Authorised
2021-03-11
31 B. PACKAGE LEAFLET 32 PACKAGE LEAFLET: INFORMATION FOR THE USER JCOVDEN SUSPENSION FOR INJECTION COVID-19 vaccine (Ad26.COV2-S [recombinant]) This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE VACCINATED BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What JCOVDEN is and what it is used for 2. What you need to know before you are given JCOVDEN 3. How JCOVDEN is given 4. Possible side effects 5. How to store JCOVDEN 6. Contents of the pack and other information 1. WHAT JCOVDEN IS AND WHAT IT IS USED FOR JCOVDEN is a vaccine used for preventing COVID-19 caused by the SARS-CoV-2 virus. JCOVDEN is given to adults aged 18 years and older. The vaccine causes the immune system (the body’s natural defences) to produce antibodies and specialised white blood cells that work against the virus, so giving protection against COVID-19. None of the ingredients in this vaccine can cause COVID-19. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN JCOVDEN DO NOT HAVE THE VACCINE IF You are allergic to the active substance or any of the other ingredients of this vaccine (listed in section 6). You have had a blood clot occurring at the same time as having low levels of blood platelets (thrombosis with thrombocytopenia syndrome, TTS) after receiving any COVID-19 vaccine. You have a previous diagnosis of capillary leak syndrome, (a condition causing fluid leakage from small blood vessels). WARNINGS AND PRECAUTIONS Talk to your doctor, pharmacist or nurse before you are given JCOVDEN if: yo Read the complete document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT JCOVDEN suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant]) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION This is a multi-dose vial which contains 5 doses of 0.5 mL. One dose (0.5 mL) contains: Adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein* (Ad26.COV2-S), not less than 8.92 log 10 infectious units (Inf.U). * Produced in the PER.C6 TetR Cell Line and by recombinant DNA technology. The product contains genetically modified organisms (GMOs). Excipients with known effect Each dose (0.5 mL) contains approximately 2 mg of ethanol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection (injection). Colourless to slightly yellow, clear to very opalescent suspension (pH 6-6.4). 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS JCOVDEN is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. The use of this vaccine should be in accordance with official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Individuals 18 years of age and older_ Primary vaccination JCOVDEN is administered as a single-dose of 0.5 mL by intramuscular injection only. 3 Booster dose A booster dose (second dose) of 0.5 mL of JCOVDEN may be administered intramuscularly at least 2 months after the primary vaccination in individuals 18 years of age and older (see also sections 4.4, 4.8 and 5.1). A booster dose of JCOVDEN (0.5 mL) may be administered in individuals 18 years of age and older as a heterologous booster dose following completion of primary vaccination with an mRNA COVID- 19 vaccine or an adenoviral vector-based COVID-19 vaccine. The dosing interval for the Read the complete document